Hong Kong Department of Health Visited Sinovac on R&D and Production of H1N1 vaccine

2009-09-08

On the morning of September 8, 2009, the HK Department of Health delegation led by Dr PY LAM, Director of Health, Dr. Kwok-Yung Yuen, Honored Consultant, Dr.Anthony W.K.CHAN, Chief Pharmacist, and Dr Thomas TSANG, Controller, Centre for Health Protection, visited Sinovac for an inspection on R&D, production of H1N1 vaccine.

After listening to the introduction on H1N1 vaccine, the delegation also visited the production line, filling and packaging plant, quality control laboratory and checked the batch records of the H1N1 vaccine. The experts of the delegation appreciated Sinovac's research and production of H1N1 vaccine.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.